Wednesday, August 5, 2009

XDx Adds $14.4M

Brisbane-based XDx, a firm working on molecular diagnostics, reported Wednesday that it has raised $14.4M in a Series G financing round. The round was led by Bristol-Myers Squibb, along with prior investors Burrill Venture Capital; Duff, Ackerman & Goodrich; Integral Capital Partners; Intel Capital; Kleiner Perkins Caulfield & Byers; Sprout Group; and TPG Biotechnology. The firm said the new funding will go towards commercial activities and new research and development. XDx currently has an approved product, AlloMap Molecular Expression Testing, which is used to identify heart transplant recipient prospects. More information »